Enjoy complimentary customisation on priority with our Enterprise License!
The erythropoietin stimulating agents market share is expected to increase by USD 4.74 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 8.9%.
This erythropoietin stimulating agents market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers erythropoietin stimulating agents market segmentation by type (epoetin alfa, epoetin beta, darbepoetin alfa, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The erythropoietin stimulating agents market report also offers information on several market vendors, including 3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., Biosidus SA, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, LG Chem Ltd., Nanogen Pharmaceutical Biotechnology, Novartis AG, Pfizer Inc., Pieris Pharmaceuticals Inc., Reliance Industries Ltd., Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd. among others.
Download Report Sample to Unlock the Erythropoietin Stimulating Agents Market Size for the Forecast Period and Other Important Statistics
The presence of a large pool of CKD patients is notably driving the erythropoietin stimulating agents market growth, although factors such as stringent government regulations may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the erythropoietin stimulating agents industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Erythropoietin Stimulating Agents Market Driver
The presence of a large pool of CKD patients is one of the factors driving the erythropoietin stimulating agents market growth. Typically, patients negatively affected by health conditions such as diabetes, high blood pressure, and glomerulonephritis are susceptible to developing chronic renal ailments. Moreover, health conditions such as high blood pressure can damage the blood vessels in the kidney and negatively affect their functioning. Hence, diseased or damaged kidneys are unable to produce the required amount of EPO, which results in a decline in the production of RBCs and ultimately causes anemia. Therefore, due to the surge in the patient population negatively affected by conditions associated with CKD, such as renal anemia, there is a growing demand for effective treatment, which will be a major growth driver for the global ESAs market during the forecast period.
Key Erythropoietin Stimulating Agents Market Trend
The growing number of CKD dialysis centers in developing economies is one of the key erythropoietin stimulating agents market trends fueling the market growth. Developing economies, such as China, India, and Brazil, are witnessing a growing prevalence of CKD, which is encouraging ESA vendors to invest in these markets. Furthermore, attempts to improve CKD treatment have led to an increase in the number of dialysis centers in developing countries, such as Brazil. For instance, in December 2021, Asia's dialysis network, NephroPlus, announced a $25 million investment in India to pursue growth opportunities across APAC. Therefore, such developments in dialysis centers in developing economies are expected to create new growth opportunities for the vendors in the ESAs market globally.
Key Erythropoietin Stimulating Agents Market Challenge
Stringent government regulations is one of the key factors challenging the erythropoietin stimulating agents market growth. Stringent regulatory guidelines and complex administrative systems to obtain market approval increase the time to market and costs associated with launching the drugs. The marketed drugs are also under constant scrutiny by the regulatory authorities to ensure the safety of consumers. For instance, in April 2015, the United States Food and Drug Administration (US FDA) issued a strong warning regarding the serious and fatal allergic reactions associated with the use of Feraheme. The US FDA had also changed the instructions for the drug and added a black box warning that outlines the side effects on the packaging. Therefore, such adverse events may impose restrictions on the use of iron drugs and negatively affect the sales growth of the global ESAs market during the forecast period.
This erythropoietin stimulating agents market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global erythropoietin stimulating agents (ESAs) market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the erythropoietin stimulating agents market during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the erythropoietin stimulating agents market encompasses successful business strategies deployed by the key vendors. The erythropoietin stimulating agents market is fragmented and the vendors are deploying growth strategies such as quality, price, service, brand image, distribution, and marketing to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The erythropoietin stimulating agents market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the erythropoietin stimulating agents market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
42% of the market’s growth will originate from North America during the forecast period. The US and Canada are the key markets for the erythropoietin stimulating agents market in North America. Market growth in this region will be slower than the growth of the market in Asia.
The increasing number of patients suffering from anemia will facilitate the erythropoietin stimulating agents market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 had adversely impacted the regional market. However, in Q1 2021, the initiation of vaccination programs led to the resumption of business operations, including the supply chain of ESAs drugs. Thus, the regional ESAs market witnessed positive growth in 2021 due to the increase in demand for healthcare and clinics and will continue to have similar growth during the forecast period.
To gain further insights on the market contribution of various segments Request PDF Sample
The erythropoietin stimulating agents market share growth by the epoetin alfa segment will be significant during the forecast period. Epoetin alfa drugs are used for treating anemia in chronic kidney disease (CKD) patients and as an anti-coagulant to lower the risk of serious blood clots. They also reduce the need for blood transfusions before certain planned surgeries that have a high risk of blood loss. These drugs can also be used in the treatment of other conditions such as human immunodeficiency virus (HIV) and cancer. Such benefits will drive the segment growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the erythropoietin stimulating agents market size and actionable market insights on post COVID-19 impact on each segment.
Erythropoietin Stimulating Agents Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 8.9% |
Market growth 2022-2026 |
$ 4.74 billion |
Market structure |
Fragmented |
YoY growth (%) |
8.3 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 42% |
Key consumer countries |
US, Canada, Germany, UK, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
3SBio Inc., Akebia Therapeutics Inc., Amgen Inc., Biocon Ltd., Biosidus SA, Dr. Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Johnson and Johnson, LG Chem Ltd., Nanogen Pharmaceutical Biotechnology, Novartis AG, Pfizer Inc., Pieris Pharmaceuticals Inc., Reliance Industries Ltd., Thermo Fisher Scientific Inc., and Zydus Lifesciences Ltd. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.